The recommended dosing regimen for TAVALISSE is individualized based on patient response and tolerability, with specific escalation and reduction protocols.

Individualized Dosing Strategy for TAVALISSE

The initial recommended dose of TAVALISSE (fostamatinib) is 100 mg orally twice daily, with or without food. After four weeks, if the platelet count has not increased to at least 50 × 10⁹/L, the dose may be escalated to 150 mg twice daily. Dose modifications, including reduction or interruption, are advised in response to adverse reactions or drug interactions. If further reduction below 100 mg/day is required, discontinuation is recommended. TAVALISSE should be discontinued after 12 weeks if platelet counts do not reach a level sufficient to avoid clinically significant bleeding.